VTX-958 is under clinical development by Ventyx Biosciences and currently in Phase II for Psoriatic Arthritis. According to GlobalData, Phase II drugs for Psoriatic Arthritis have an 84% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how VTX-958’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
VTX-958 is under development for the treatment of Crohn’s disease, plaque psoriasis, systemic lupus erythematosus and psoriatic arthritis. It is administered through oral route. The drug candidate acts by targeting non receptor tyrosine protein kinase (TYK2).
Ventyx Biosciences overview
Ventyx Biosciences is a clinical-stage biotechnology company that discover and develops novel drugs for inflammatory diseases and autoimmune disorders. The company’s pipeline include VTX958, a TYK2 inhibitor for the treatment of various autoimmune diseases; VTX002, S1P1 receptor modulator for the treatment of ulcerative colitis and others. Ventyx Biosciences headquartered in Encinitas, California, the US.
For a complete picture of VTX-958’s drug-specific PTSR and LoA scores, buy the report here.